title: Relevance of fluoroquinolone use in hospitals in the Lorraine region of France before and after corrective measures: an investigation by the Antibiolor Network.
abstract: OBJECTIVE
  This study of fluoroquinolone use was carried out before and after an educational intervention run by Antibiolor, a regional network to all hospitals in the Lorraine region of France.
  
  
  METHODS
  The relevance of fluoroquinolone prescription according to regional guidelines was assessed using a standard card filled out by physicians and pharmacists at the voluntarily participating hospitals. A therapeutic index of adequacy was established for each card. The initial survey took place in January 2008, with feedback and proposals for corrective measures in January 2009. The second survey was organized in June 2009. The results of the 2 surveys were compared.
  
  
  RESULTS
  Twenty-four hospitals completed a total of 1336 cards in the first survey (S1) and 944 cards in the second (S2). The appropriateness of indications for fluoroquinolone use improved by 57% between the 2 surveys. All the criteria analyzed (choice of drug, dosage, treatment duration) were significantly improved in S2 compared to S1, as was the adequacy index (70% improvement).
  
  
  CONCLUSIONS
  In view of the consequences of fluoroquinolone use, many hospitals in Lorraine were keen to participate in this study, confirming its feasibility over a large area. In view of the study results, the book of guidelines was re-examined and republished at the conclusion of S2. Greater adherence to guidelines was noted in S2, demonstrating the benefit of assessing the situation thoroughly before proposing corrective measures and evaluating their impact.
authors.affiliation: Department of Infectious Diseases, CHU Nancy, allée du Morvan, Vandoeuvre les Nancy, France. thanh.lecompte@chu-nancy.fr
authors.forename: Thanh
authors.initials: T
authors.lastname: Doco-Lecompte
authors.forename: Beatrice
authors.initials: B
authors.lastname: Demore
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hénard
authors.forename: Lakshmi
authors.initials: L
authors.lastname: Rughoo
authors.forename: Christine
authors.initials: C
authors.lastname: Burty
authors.forename: Gregory
authors.initials: G
authors.lastname: Rondelot
authors.forename: Emilia
authors.initials: E
authors.lastname: Frentiu
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Desmots
authors.forename: Lorraine
authors.initials: L
authors.lastname: Letranchant
authors.forename: Celine
authors.initials: C
authors.lastname: Robert
authors.forename: Christian
authors.initials: C
authors.lastname: Rabaud
authors.forename: Thierry
authors.initials: T
authors.lastname: May
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002648:Child; D011307:Drug Prescriptions; D004363:Drug Utilization; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000627:therapeutic use*; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones